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1 Introduction
1.1 Aim of this White Paper
The aim of this White Paper, based on the 2011 Gaithersburg
Workshop, is to identify new proteomics analytical tools and
applications that can bring broad benefits to the biosciences
and to the US economy. This report highlights opportunities
for multiple US Government agencies to pursue their priori-
ties with a coordinated R&D effort that integrates proteomics
Correspondence: Dr. Gilbert S. Omenn, University of Michigan,
2065 Palmer Commons, Ann Arbor, MI 48109–2218, USA
E-mail: gomenn@umich.edu
Fax: +1 734-615-6553
Abbreviations: NCI, National Cancer Institute; NIST, National In-
stitute of Standards and Technology; NSTC, National Science
and Technology Council; SNP, single-nucleotide polymorphisms;
SRM, selected reaction monitoring
into major life sciences initiatives. The prospects for budget
synergies for the agencies and for a large multiplier in eco-
nomic activity and job growth in the relevant applied biotech-
nology sectors can make this opportunity attractive even in
difficult budget times. A 2011 Battelle report [1] estimated an
$800 billion economic impact over 22 years from the Nation’s
investment in genomics and biotechnology; proteomics can
play an analogous role in catalyzing economic benefits for
the next stage of biotechnology, particularly since proteins
are two steps closer than genes to most biological phenom-
ena and diseases. In addition, this initiative would enhance
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the role of US scientists, institutions, and companies in a
growing, high-profile international endeavor.
1.2 Vision of a grand challenge for proteomics
The vision of a grand challenge for proteomics is to make bold
advances in utilizing and advancing the technology platforms
and knowledge bases for quantifying and characterizing pro-
teins in functional protein networks, thereby facilitating soci-
etally important applications in health, agriculture, nutrition,
energy, environment, and national security.
The proteome is the operating system for nearly all biolog-
ical functions. It is the link between the genome and phe-
notypes. It undergoes dynamic changes in different cells and
organs, during development, in response to environmental
stimuli, and in disease processes. Understanding the dynam-
ics of protein interactions with other proteins, nucleic acids,
and metabolites is the key to delineating biological mecha-
nisms and understanding disease.
1.3 Background for the workshop
In 2009, the Office of Science and Technology Policy issued a
call for grand challenges in biotechnology. National Institute
of Standards and Technology (NIST) submitted a proposal
for a workshop and white paper on new technologies for
proteomics, which was approved by the National Science and
Technology Council (NSTC) Biotechnology Subcommittee.
The Workshop convened by Michael Amos of NIST, Leroy
Hood of the Institute for Systems Biology, Ruedi Aebersold of
ETH-Zurich, and Keith Yamamoto of UCSF was held on 14–
15 February 2011 in Gaithersburg, MD. Attendees are listed
in the Appendix (additional participants) and as coauthors
above.
Further stimulus for this Workshop came from recent re-
ports from the National Research Council on “A New Biology
for the 21st Century” [2] and “Research at the Intersection
of Physical and Life Sciences” [3]. Those reports identified
a need for technologies to understand biological systems in
sufficient depth to fulfill societal goals of advancing and pro-
tecting health, bioenergy, the environment, food production,
green manufacturing, and national security. These reports
identified the need for new research approaches for studying
biological systems that bring together the physical, chemical,
biological, and computational sciences.
1.4 Baseline for the grand challenge for proteomics
There have been dramatic advances in the past 5 years in iden-
tification and quantification of proteins in biological systems,
generating confidence that a complete parts list of the pri-
mary products of the 20 300 protein-coding genes in humans
and corresponding whole proteomes of other organisms is
within reach [4]. The targeted MS approach of Selected Reac-
tion Monitoring (SRM) led by American and Swiss scientists
has produced the SRM Atlas with spectra for approximately
six informative peptides (signatures) for each of the 20 300 hu-
man protein gene products and a corresponding atlas for all
of the 6500 yeast protein products [5,6]. For accurate quantifi-
cation, stable heavy isotope-labeled peptide reagents are now
readily available for all of these peptides through commercial
sources. For increased signature peptide detection, antipep-
tide capture reagents can reduce the concentrations for the
limits of detection by current instrumentation by two orders
of magnitude [7].
Remarkable advances in MS instruments now permit iden-
tification of 7000 to 10 000 proteins in single studies of cul-
tured human cell lines and other specimens with the latest
Orbitrap hybrid mass spectrometers [8, 9]. The detection of
dozens to hundreds of peptides simultaneously by SRM coor-
dinates, derived from the SRM Atlas and applied to nonscan-
ning triple-quadruple MS instruments from multiple manu-
facturers, provides unprecedented targeted quantitative anal-
ysis. On the horizon is the enhancement of top-down MS
that yields sequences of proteins (currently up to about 50
kDa molecular mass) without requiring the variable steps
of proteolytic digestion and peptide fractionation. US man-
ufacturers are at the forefront of many of these instrument
advances.
Due to PTMs, single-nucleotide polymorphisms (SNPs),
and alternative splicing of proteins, there are numerous dif-
ferent structures of individual primary products, making the
dimensions of this grand challenge much larger than the hu-
man genome sequencing project. PTMs can be detected with
Electron Transfer Dissociation (ETD) collision spectrome-
try [10]. Genomics alone cannot interrogate and delineate
this protein diversity and its functional consequences.
The Human Protein Atlas, led by Uhlen et al. in Sweden,
is a great example of integrating genomics and proteomics,
using predicted protein sequences and epitopes to produce
antibodies that can capture proteins and map by immuno-
histochemistry the expression and intracellular localization
of each specific protein in 46 tissues of humans. The Protein
Atlas now covers 12 238 proteins and is projected to reach
14 000 of the 20 300 proteins with version 10 in September
2012 [11]. The antibodies developed in this effort are reagents
applicable to many biological studies. For example, these pro-
tein epitope signature tagged peptides (PrESTs) have been
labeled with stable isotopes and spiked into cell lysates to
facilitate absolute quantitation of the targeted proteins with
MS [12].
Finally, a well-coordinated, global, curated data and knowl-
edge base for proteomics findings is essential for broad
dissemination and secondary analyses. Such a knowledge
base, covering about 13 000 proteins, has been created
through sustained major European funding for the Swiss
Institute for Bioinformatics (SwissProt, NeXtProt) and the
European Bioinformatics Institute (UniProt, PRIDE) and
through US efforts that provide standardized reanalysis of
MS-based proteomes by the Institute for Systems Biology
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in Seattle (Peptide Atlas, SRMAtlas, PASSEL). These global
resources are linked through the EU-funded ProteomeX-
change Consortium (www.proteomexchange.org). Identify-
ing the remaining proteins, characterizing their many vari-
ants due to SNPs, RNA splicing, and PTMs, and integrating
proteomic and genomic analyses through biological networks
and protein and RNA complexes is truly a feasible grand
challenge.
Meanwhile, the international Human Proteome Organi-
zation (HUPO) has stimulated and led ten initiatives on or-
gan proteomes (liver, brain, kidney, and heart), biofluid pro-
teomes (plasma/ serum [13], urine, and cerebrospinal fluid),
model organism proteomes, protein standards, and antibod-
ies. In 2010, HUPO announced a global Human Proteome
Project in which numerous countries have stepped forward
to lead efforts focused on the proteins coded for by genes
on individual chromosomes and on protein interactions and
networks that mediate a wide range of biological and disease
processes [14, 15]. An NSTC initiative on bold new technolo-
gies represents a distinctive opportunity for global leadership
by the United States that would be a major contribution to
the Human Proteome Project.
Apart from multiyear NIH center grant programs renewed
in 2009 by the National Heart, Lung, and Blood Institute
(NHLBI) and in 2011 by the National Cancer Institute (NCI)
for Clinical Proteomics Technologies Consortia, proteomics
support in the United States is mostly embedded in applied bi-
ology project grants under the NCI Early Detection Research
Network and clinical proteomics programs of the NHLBI, Na-
tional Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institute of Allergy and Infectious Dis-
eases (NIAID), and other institutes and agencies. The Work-
shop participants concluded that the time is ripe to develop
and apply bold advances in next-generation proteomics tech-
nology platforms with specificity, depth, and quantification to
characterize the nature and function of the human proteome.
Also in late 2011, the NIH convened a Human Proteome
Workshop that focused on protein interactomes, biological
networks, and the path to clinically useful biomarkers [16].
2 Linking the genome to normal and
disease phenotypes: The key role of
proteins in realizing the full potential of
the human genome project
The Human Genome Project has transformed many aspects
of human biology and medical research. It was made feasible
by audacious goals and successful new technology platforms.
It overcame severe initial skepticism about feasibility and pay-
off. The essential first stage of the Human Genome Project
was to design and use potent new technology platforms for se-
quencing and synthesizing DNA and protein molecules [17].
This radically changed the study of genes and gene regula-
tion in all organisms. The Genome Project democratized ge-
netics, making all genes accessible to biologists everywhere;
generated a comprehensive “parts list” of genes and, by infer-
ence, their protein products; stimulated a holistic approach
to studying biological complexity through systems biology;
catalyzed the emergence of a whole new commercial sector
with high-throughput instruments, reagents, services, and
products; pioneered the large-scale application of computer
science and informatics to biology; demonstrated the power
of open-source data and data resources; produced the first
rigorous standards for biological data; facilitated access to the
genomes of plants, animals, and microbes with stunning new
findings; revolutionized our thinking of evolution through
comparative genomic studies; and transformed our thinking
about medical diagnostics and targeted therapies. Neverthe-
less, there are many scientists, public figures, and journalists
concerned about the slow progress in transforming medicine
and public health.
By analogy, the grand challenge in Proteomics can have
spectacular results similar to those of the genome project –
democratizing the study of proteins, creating a broader and
deeper parts list for systems biology, characterizing protein
interactions and biological networks that mediate physiolog-
ical and pathological processes, building an economic en-
gine for instruments and reagents and omics-based tests,
and scientifically linking all species to address societal goals
for health, food, energy, environmental sustainability, and
national security. Based on successes in many fields, the
enunciation of a “grand challenge” can actually contribute
to its solution, by stimulating essential technology devel-
opment and by identifying presently inaccessible gaps in
technologies [18].
An important point for emphasis is a holistic or systems
approach to deciphering the complexity of biology and dis-
ease. A simple analogy for systems thinking is that of un-
derstanding how a radio converts electromagnetic waves into
sound waves. This could proceed in three steps: first, taking
the radio apart and cataloguing all of the components; sec-
ond, determining the functions of the individual parts; and,
third, putting the components together in circuits (networks)
and learning how the networks collectively contribute to con-
verting radio waves into sound waves. The Genome Project
identified all genes and by inference all proteins. For the
last 40 years, biologists have studied the individual compo-
nents of life (genes and proteins). The goal now is to under-
stand how these proteins and genes are integrated into the
biological networks and molecular machines that function
to convert the information of the genome and the environ-
ment into the phenotype of the organism. A critical aspect
of systems approaches is deciphering biological and medical
complexity by following the dynamics of these interactions,
in part with technologies that can identify and quantify all
proteins, protein isoforms, and protein interactions of living
organisms.
We are at an inflection point for proteomics technologies.
As with the early years of the Human Genome Project, we can
“catch the wave” and create a transformational future. This
mission goes far beyond creating a parts list of all proteins.
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2.1 Proteins
Proteomics technology development and applications can
dramatically augment genomic efforts. The proteome arises
as a result of an enormous amplification of complexity that
occurs stepwise in the biological translation of information
from DNA to RNA to proteins. Proteins are:
(i) the effector molecules that execute many critical func-
tions of life, whose lesions lead to diseases.
(ii) the major components of biological networks that con-
trol many functions of cells and their intercellular in-
teractions, by capturing, transmitting, and integrating
biological information and passing it on to molecular
machines.
(iii) the cell-surface receptors and channels that sense the en-
vironment and bring this information into living cells,
with collisions between the digital information of the
genome and the diverse insults from environmental ex-
posures determining susceptibility or resistance to var-
ious diseases.
(iv) the regulators and downstream mediators of gene ex-
pression and biological networks.
(v) the targets of nearly all drugs and, increasingly, them-
selves effective drugs.
2.2 Complexity of the proteome
The 20 300 protein-coding genes in humans give rise to per-
haps a million different protein isoforms in the human pro-
teome. While there are two nearly identical copies of every
autosomal gene in all nucleated cells, there may be anywhere
from zero to millions of copies of a protein in a given cell, rep-
resenting an enormous range of concentrations, which can
vary strikingly in response to internal and external stimuli.
Thus, quantitative real-time measurements are essential for
assessing the dynamics of the proteome. Each gene-encoded
protein has numerous isoforms that reflect mutations, gene
fusions, alternative splicing, mRNA editing, chemical modifi-
cations, and proteolytic processing of the proteins. Ultimately,
we must develop technology platforms to identify, quantify,
and determine the functions of these many protein isoforms.
Proteins interact with other proteins, nucleic acids, lipids,
and other small molecules, including tightly bound metal
atoms, to form molecular machines mediating movement
or ion flow, membrane structures, large interactive biolog-
ical networks, and gene regulatory complexes. Finally, pro-
teins are dynamic in ways genes are not: they can undergo
rapid changes in 3D shape, change locations within a cell,
change rates of secretion or release to the circulating blood
and lymphatics, and function in molecular machines and bio-
logical networks. Thus, proteins represent multidimensional,
dynamic, analog information rather than linear, mostly static
digital information.
The Grand Challenge for Proteomics is to develop tech-
nologies and research resources capable of identifying and
characterizing these molecular species and following their
dynamic molecular interactions in health and disease.
3 Emerging proteomics technologies that
jump-start the grand challenge
3.1 MS
MS methods currently are the backbone of experimental pro-
teomics for global protein analyses. An impressive, rapidly
expanding array of instruments matched to particular com-
plementary applications has galvanized progress, as noted
previously [4]. MS-based proteomics was greatly accelerated
by information from the Human Genome Project for se-
quence matching. The goals for innovation are: to markedly
increase signal/noise in identifying and sequencing peptides,
to detect and quantify specific peptides with PTMs, SNPs,
or splicing, and to greatly increase the throughput to make
assays useful for clinical studies and population studies. An-
other critical area is to be able to follow closely the dynamics
of how proteomes change (in concentration and in structure)
in response to environmental signals and disease. Protein-
capture reagents can recognize and pull down targeted pro-
teins and multimolecular complexes, followed by identifica-
tion with MS.
Proteins emerging from biomarker discovery experiments
can be assayed through distinctive peptides with SRM. A key
element is greater sensitivity of identification of proteins in
complex mixtures like tissue lysates and plasma. An excit-
ing example is SWATH, Sequential Window Acquisition of
all Theoretic Mass Spectra. This approach records a perma-
nent digital record of fragment ion spectra of each object in
a sample, which can be identified from the corresponding
reference spectrum in the SRM Atlas. SWATH maintains
the dynamic range of SRM but vastly increases its coverage
per unit time, essentially becoming a protein microarray [19].
This technique will be powerful in more comprehensively as-
sessing proteome dynamics – a critical need of contemporary
proteomics and systems biology.
3.2 Protein-capture reagents
Protein-capture reagents can identify, quantify, localize, and
purify specific proteins for a wide variety of studies. Promis-
ing reagents include polyclonal and monoclonal antibodies,
aptamers, peptides, and DNA–peptide hybrids. The desired
attributes are highly avid, highly specific even in complex
specimens, renewable, scalable, robust, stable in storage, easy
to mass-produce with high quality, easy to transfer, relatively
inexpensive, and with well-defined uses. A special attribute
of certain emerging reagents is bifunctional chemistry that
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enables target molecules to be detected in vivo through the
protein-capture agents and associated reporter groups.
An advance based on click chemistry is the generation of
multivalent peptide reagents [20]. A large D-amino acid pep-
tide library of 6-mers is screened against the protein to be cap-
tured to identify low-affinity anchor peptides. Additional low-
affinity peptides are identified similarly. The anchor peptide
and additional peptides are linked in three-dimensional orien-
tations by click chemistry to form a dimer and then a trimer,
which can have affinities and specificities that match or ex-
ceed the best monoclonal antibodies. These agents are also
useful for in vivo imaging. Recently, these reagents have been
directed at specific epitopes on proteins, such as a phosphory-
lated versus a nonphosphorylated site. Hence, they can follow
important biological modifications of proteins and have the
potential to become effective drugs.
Surface-based bioaffinity measurements utilizing nano-
particles, aptamers, enzymatic transformations, and intra-
cellular signal amplification methods can impart higher
sensitivity and selectivity to analyses of complex protein
networks.
3.3 In vivo molecular imaging
Protein-capture agents can be designed for delivery to tar-
get tissues in model organisms or humans for physiological,
diagnostic, and therapeutic purposes. Imaging is a key appli-
cation for protein-capture agents. Visualization can be me-
diated by fluorescence, luminescence, radioactivity, or other
labeling methods, and can be combined with nanotechnology
for carriers. The key to understanding many physiological
and disease processes is to follow the dynamics of molec-
ular transitions in vivo. Small, high-affinity/high-specificity
reagents with appropriate reporter groups are essential for
such imaging technologies. Use of fluorescence recovery af-
ter photobleaching (FRAP) has provided measurements of
proteins and their complexes down to single-molecule sen-
sitivity [21]. Greater diversity of imaging technologies will
be helpful. Next-generation imaging tools will characterize
complex intracellular structures, such as virus capsid shells
and ion channel membrane pores. They will help visualize
complex protein interactions and possibly distinguish differ-
entially expressed isoforms of target proteins.
3.4 Ultrasensitive single-cell and single-molecule
analyses of proteins
Single-cell analyses are becoming a fundamental approach
in cell biology. The key technology platforms utilize pow-
erful adaptations of microfluidics, nanotechnology, and
new chemistries. For example, Rissin et al. developed a
single-protein molecular detection strategy by “singulating”
enzyme-linked protein molecules on microspheres in arrays
of 50-femtoliter reaction chambers with digital readout of flu-
orescence, and demonstrated this highly sensitive approach
on prostate-specific antigen and tumor necrosis factor-alpha
in serum [22]. Single-cell and ultrasensitive protein analyses
will enable investigations of the differential roles of distinct
cells in complex mixtures in tissues or blood.
3.5 In silico protein folding approaches
A rapidly growing list of diseases caused by misfolding of
proteins (from prion brain disease and Alzheimer disease to
diabetes [23]) puts a focus on connecting proteomics with
structural biology. Three-dimensional structures can provide
fundamental insights into the protein functions not only of
humans, but also plants, animals, and microbes, bridging
protein chemistry and proteomics. For instance, computa-
tional modeling of conformational changes due to exon swap-
ping in pairs of differentially expressed protein splice variants
in cancers has shown the power of modeling and inference
for functional consequences [24]. In silico protein folding
may also be important for determining whether gene vari-
ants identified in the analyses of human genome sequences
lead to proteins whose structures are sufficiently altered to
become nonfunctional.
3.6 Computational visualization and integration of
molecular findings across the omics platforms
The goal is to generate predictive, actionable, testable models
of biological and disease processes and responses to external
stimuli. This requires connecting and integrating genomic,
epigenomic, transcriptomic, proteomic, metabolomic, and
many types of phenotypic data. In taking a systems approach
to understanding biological processes, it is essential first to
identify the relevant parts list; then one must integrate these
different types of “parts” into descriptive, graphical, or mathe-
matical models for biological networks that give insights into
how their dynamic behavior captures, transmits, integrates,
and passes on information to the molecular machines that
execute the functions of life. Tools such as Cytoscape and its
many plug-ins facilitate graphical presentation of such com-
plex information and molecular relationships.
3.7 Computational and mathematical methods
and models
Validation and quantification of the data and insights from
proteomics and other omics technologies depend on compu-
tational sciences and scientists capable of bridging the bio-
sciences and bioinformatics. At the highest level, there is the
question of how one turns data into knowledge. One of the
grand challenges in biological measurements is to validate
the quality of the data and to be able to deal with the tremen-
dous signal-to-noise and overfitting challenges that come with
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large data sets [25]. We also need to think about how to effec-
tively capture, store, mine, integrate, and finally model these
data – so that predictions and actionable consequences result.
We need to create the tools that will let biologists and medical
researchers utilize the power of proteomics through assays
that cover relevant biological networks and make it easy to
follow their dynamics. Novel algorithms for statistical mod-
els are needed to decrease false-positive peptide and protein
identifications, increase signal/noise ratios, sequence longer
peptides, and characterize high-charge states.
Computation is transforming biology, just as it has trans-
formed many other fields. Data dimensionality is enormous
and growing rapidly; in 10 years, we may have all kinds of
biological systems and even individual patients with billions
of data points to be linked through genotype–phenotype cor-
relations.
4 Measurable goals and 5-year
deliverables from a grand challenge for
proteomics technologies
In setting goals and deliverables, let us recapitulate the key
features of proteins for global analysis of the proteome: (1)
while genes are digital in nature with a four-letter language,
proteins are analog with a 20 letter language – genes op-
erate in a one-dimensional world and proteins in a three-
dimensional world; (2) proteins lack the molecular comple-
mentarity of DNA and hence cannot be amplified prior to
measurement – thus, we must develop ultrasensitive tech-
niques to measure and analyze a few or single protein
molecules; (3) proteins have extreme complexity due to mod-
ifications by gene mutation, RNA editing, RNA splicing, up
to 400 types of covalent changes, and protein processing;
(4) proteins are dynamical, changing their three-dimensional
structures, positions in the cell, concentrations at different
cellular sites, sequences, covalent chemistries, and interac-
tions with other proteins and molecules of many types in
response to endogenous and exogenous stimuli; (5) proteins
exhibit a 106 dynamic range in tissues and a 1012 dynamic
range in blood, making quantification essential; (6) there are
two fundamental ways of identifying and quantifying pro-
teins: (a) MS and (b) protein-capture agents (e.g. antibodies);
and (7) we ultimately need to be able to measure proteins in
all of their dimensions in the context of the single cell, the
fundamental unit of function in living organisms, which will
require the development of microfluidic and nanotechnology
techniques for handing single cells.
With these specific challenges in mind, here are goals and
deliverables we consider feasible over the coming 5-year pe-
riod:
(i) Enhance the sensitivity of MS-based protein identifi-
cation by 100×–1000× in tissues and plasma to match
the most sensitive antibody (ELISA) assays and monitor
the dynamics of low-abundance proteins with high bio-
logical relevance. This is the scale of technological gain
that made the Genome Sequencing Project feasible.
The required amount of material for protein analyses
will move from 106 cells to 103 cells, and then toward
single cells in concert with additional technologies (be-
low).
(ii) Create MS reference spectra for peptides of all proteins,
including those with PTMs (glycosylation, phosphory-
lation, acetylation, ubiquitinylation, many others); gain
value from the substantial proportion of high-quality
spectra not yet recognized as modified peptides; and
expand the existing PeptideAtlas and newly produced
SRM Atlas. Make all of these resources publicly avail-
able through NIST (as for SpectraST), NIH, and other
federal agencies. Connect MS data with protein capture
data through the Human Protein Atlas.
(iii) Deploy microfluidics and nanotechnology together
with proteomics to permit sensitive analyses of single
cells and very low-abundance protein molecules and
their interactions with other proteins, nucleic acids, and
small molecules. These technologies enable miniatur-
ization of sample size, integration of multiple chemi-
cal procedures in the assay, parallelization of measure-
ments to increase throughput, and automation of as-
says.
(iv) Enhance throughput of proteomics assays so that re-
producible, sensitive results can be obtained on many
hundreds of specimens per day, useful for drug devel-
opment, patient monitoring, epidemiological studies of
populations, and complex time-course experiments tied
to signaling pathways, biological networks, gene regu-
lation, and disease phenotypes. Ultimately, carry out
high throughput proteomics assays by protein-capture
agents arrayed on microfluidic chips so that thousands
of measurements may be made in a few minutes on
samples from a fraction of a droplet of blood (or solubi-
lized tissue). These assays will revolutionize our ability
to understand biological functions, present new strate-
gies for diagnostics, open up exciting new possibilities
for identifying effective drug targets – and then enable
the efficient selection of drugs for these targets.
(v) Move massive proteomics data resources to the cloud
along with the appropriate analytic tools so that very
large-scale data analysis may be managed from desktop
computers; of course, this requires figuring out how to
input these data into the cloud efficiently and rapidly.
This capability will link sustainable data repositories
and proteomics atlases, with open access, and will have
data links and analytical tools embedded to facilitate
modeling of phenotypic responses.
(vi) Develop software that will let any biologist integrate
proteomics data into the broad spectrum of omics
data (epigenetic, genomic, transcriptomic, miRNA,
metabolomic, and interactomic) – to create metadata
structures from which predictive models about bio-
logical systems can be generated. This begins with
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2012, 12, 2773–2783 2779
enhanced proteomics workflows to process terabytes
of LC/MS-MS data with scaling and high throughput
from thousands of samples. A current domain for in-
tegrative omics analysis is pathway-based cancer thera-
pies. Another realm for tools that integrate omics data
is to characterize organisms from meta-proteomes of
complex human microbiomes and the microbial com-
munities that dominate the Earth’s biomass.
(vii) Adopt standardized criteria and establish software for
quality assessment and quality assurance of the various
types of proteomics data [26].
(viii) Apply these powerful proteomics approaches to the pro-
teomes of important model organisms – microorgan-
isms, Arabidopsis, Drosophila, Caenorhabditis elegans, ze-
brafish, mice, rats, and primates – to enable compara-
tive proteomics.
5 Expected impacts from the grand
challenge in proteomics for sectoral
S&T goals and for economic growth
5.1 Human health (NIH, lead)
Large-scale analysis of proteins has been inspired by the re-
alization that the proteome is inherently more complex and
more relevant to function than the genome alone. Software-
driven data analysis and inference is vital for understanding
complex diseases, disease prognosis and progression, per-
sonalized treatment selection, drug targeting, and drug safety
assessments.
Strategies for personalized, predictive, preventive, and par-
ticipatory (P4) medicine depend on an integrated omics-
based R&D approach [27]. Protein and complementary RNA
(mRNA, miRNA, lncRNA) molecular signatures for functions
and dysfunction of each organ in the body and for major
disease processes will contribute importantly to diagnosis,
prognosis, and monitoring of therapeutic and preventive in-
terventions. Such biomarkers will help detect early disease,
monitor disease progression, stratify patients with a common
diagnosis like Alzheimer disease or post-traumatic stress into
subtypes for proper impedance match with emerging thera-
pies, and monitor desired and adverse responses to therapy.
A pilot example is serum profiling of liver fibrosis due to
hepatitis C [28]. The quantification of proteins in complex
mixtures will be key to making blood and other biofluids win-
dows for surveying the health and disease status of individual
patients. New technologies that can measure more sensitively
and more specifically the key isoforms of proteins in tissue
specimens or in the circulating plasma will make proteins
sensors of our environmental exposures, risk factors, and
microbiome influences.
We realize from the extended and continuing period of in-
cubation of genomics into clinical practice that our perspec-
tive must extend beyond the first 5 years. Simultaneously, we
must learn how to practice P4 Medicine without loss of pri-
vacy and confidentiality or excessive cost. In fact, an explicit
goal should be to moderate costs through more effective and
efficient health care and preventive medicine. Input from the
public, federal, and state perspectives will be important to
meet these challenges.
5.2 Agriculture and food (USDA, lead)
The Green Revolution of the 20th Century transformed agri-
culture by scientifically increasing productivity of crops and
nutritive value of foods. Those gains hit their peak recently.
Fortunately, improvements in remote sensing, transporta-
tion, weather prediction, and recombinant DNA technology
are transforming agriculture again. This process plays out
over decades. Thus, there is a critical need for long-term,
sustained investments in agricultural R&D through the US
Department of Agriculture, international agencies, and com-
panies. Plant genomics and proteomics are some of the most
exciting and productive areas of omics research. The inte-
gration of all of the omics including proteomics into pre-
dictive models will be key for redesigning plant genes to
optimize nutrition, taste, durability, resistance to infectious
agents, and other objectives. Detailed knowledge is required
for the different plant and animal species and for character-
izing adaptations to changing crop conditions, especially in
light of climate perturbations. Plants and animals also are
excellent models for learning how genetic and environmen-
tal inputs are integrated by all living organisms. Arabidopsis
has become recognized as one of the key model organisms
in proteomics and all of biology. Complete SRM assays for
all of its proteins will transform our ability to decipher its
complexity in the service of improving agricultural practices.
Proteins and protein functions are at the heart of numer-
ous questions about understanding crop and livestock bi-
ology, increasing productivity, and enhancing resistance or
other adaptations to environmental stressors. Proteins can
be biomarkers for many properties of crops and livestock
and of the food products throughout the many steps of the
food chain to animal and human consumers. Significant hu-
man public health goals are to increase the nutritional value
of common foods, as well as designing foods to fit specific
metabolic disorders (nutrigenomics/nutriproteomics) and to
help mitigate the rapidly growing problem of obesity, espe-
cially childhood obesity. The understanding of PTMs and
protein–protein interactions through network analysis will
be crucial to gaining benefits from directed improvements in
diets and in food quality.
5.3 Energy and environment (NSF, DoE,
EPA, DoD leads)
A very interesting goal for proteomics is to create a “read-out”
for the “health” of ecosystems. One baseline is the character-
ization of microbial communities, which have evolved stun-
ningly diverse capacities for altering the chemical forms of
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most elements of the periodic table, selectively interconvert-
ing organic molecules, producing valuable products through
fermentation, and communicating and competing under di-
verse conditions. They may be mobilized to break down re-
fractory organic molecules like chlorinated fluorocarbons,
lignin, and cellulose; remove actinides like uranium from
aquifers or waste streams; and bioleach copper from sulfide
minerals. Proteomics capabilities could be tapped to develop
alternative bioenergy sources and understand and enhance
carbon sequestration. All of these goals require knowledge
of the interrelated processes of plants and microbial commu-
nities and their links to biogeochemical cycles. Participants
in this Workshop were optimistic about applying emerging
knowledge of proteins in pathways that might shift the biofuel
feedstock to currently intractable parts of cells, thus reducing
the impact of biofuel production on available supplies and
prices of foods, especially corn. If biofuel production could
be scaled sufficiently, with net energy gain, it might help
reduce dependence on imported oil.
Another focus is the balance of light utilization and pro-
tection against oxidative species in photosynthetic plants
and algae; proteomics research is expected to provide in-
sights into photosynthetic processes and carbon, nitrogen,
and water cycles. Microbes in the plant environment fix ni-
trogen, mineralize nutrients from decaying organic matter,
scavenge phosphorus, produce plant growth promoters, aid
soil structure, and protect against disease agents. Proteomics
studies will contribute to characterizing new genomes and
their gene products, modeling of stable states, communi-
ties, and ecosystems spanning all scales from molecular
to global. Proteomics will provide useful knowledge about
these and many other features of symbiosis and systems
biology.
5.4 National security and counterterrorism (DoD,
DHS, NIH)
Advanced proteomics may have special value through the use
of proteins in threat detection, prediction, and deterrence.
Many national security applications focus on biological re-
sponses to pathogens, chemical agents, and radiactive expo-
sures, as well as forensic goals such as attribution of samples
of unknown origin. Improved proteomics technologies will
advance knowledge of biological mechanisms of pathogen–
chemical–radiation exposures and responses, and accelerate
development of biomarkers for early detection, diagnosis, and
prognosis. Of course, higher throughput, greater sensitivity,
and better reproducibility are features of high salience in this
domain, as in biomedicine. Contributions of proteomics to
vaccine production for military populations are also highly
desired. Use of proteins as biomarkers or diagnostic agents
would be valuable through biometrics, biofiltering, and biode-
tection for surface, air, and seafaring transportation and for
monitoring of foods both for national security and for general
consumer safety.
5.5 Economic impact
We have learned from the development of the multiple dis-
ciplines in biotechnology and from the Human Genome
Project that whole industries, new employment categories,
and very large economic gains can and do result from innova-
tion and investment in science and technology. In May 2011,
the Battelle Technology Partnership Practice issued a report
“Economic Impact of the Human Genome Project – How
a $3.8 Billion Investment Drove $796 Billion in Economic
Impact, Created 310 000 Jobs and Launched the Genomic
Revolution” [1]. In 2011 dollars, that core investment is val-
ued at $5.6B. The direct economic output during 1988–2010
was estimated at $265B of the $796B. The overall conclusion
is that the payoffs can be very large for bold projects such as
a Human Proteome Project. In this case, many of the hoped-
for developments are still in the early stages of incubation
and multiyear development pipelines. We are poised, after
a decade of gestation and progress, for major impacts from
proteomics.
Participation in this NSTC/NIST Workshop by scientist–
managers from many federal R&D agencies showed the inter-
est in tapping proteomics technologies and stimulating major
advances in proteomics for applications in each of their sec-
tors. Despite the current budgetary challenges, it would be
desirable to invest in the scientifically promising and eco-
nomically rewarding future of proteomics, including prior-
ity allocation of funds for development of next-generation
technology platforms and associated informatics and
databases.
There are estimates of the proteomics marketplace and
projections of growth over the coming years. Front Line
Strategic Consulting Inc. (San Mateo, CA, USA) projected
$2.68B for the proteomics market in 2008, growing from
$1.5B in 2003, according to The Industrial Physicist [29]
(2005). That represented a 12% compound annual growth
rate (CAGR) in the four segments of protein separation,
protein characterization, content and bioinformatics, and
services. Companies identified included Amersham (now
GE Healthcare), Applied Biosystems Inc. (now Life Tech-
nologies), BioRad, Micromass-Waters, and Thermo-Electron.
Global Industry Analysts Inc. (www.strategyr.com) projected
further growth to $6.1B by 2015, according to BioMed
Trends, Sept 2010, covering 168 companies, including Ag-
ilent, BioRad, Bruker Daltonics, GE Healthcare, Life Tech-
nologies, Perkin Elmer, Shimadzu, Sigma Aldrich, Thermo-
Fisher, and Waters. These figures are indicators of high
potential.
Meanwhile, there are substantial investments in competi-
tor economies around the world. The EU has invested re-
peatedly in large proteomics projects, top laboratories, net-
works of laboratories in member countries, and data re-
source institutions. Sweden’s government and foundations
have made remarkable investments reflected in the Hu-
man Protein Atlas. China has announced very large in-
vestments; Genome Engineering News 1 September 2011
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reported 250 companies in the genomics plus proteomics
space in China with a CAGR of 35% moving a current mar-
ket of $175M toward $655M for 2015 [30]. In 2012, the
European Bioinformatics Institute announced that it will
provide storage for raw mass spec data as part of its Pro-
teomics Identifications Database, PRIDE, funded by the EU.
The counterpart data repositories and data-sharing functions
in the United States (Peptidome at NIH, Tranche at the
University of Michigan, and PeptideAtlas at the Institute
for Systems Biology) have been unable to secure sustained
funding.
Proteomics is already a multibillion dollar enterprise with
double-digit CAGRs. Its range of applications mirrors that of
genomics and biotechnology more broadly. It is very likely to
be a major contributor to job growth and economic progress,
with impacts in multiple sectors.
6 Interagency opportunity to address the
grand challenge in proteomics
technologies
The NSTC of the White House Office of Science and Technol-
ogy Policy provided the aegis for the February 2011 Gaithers-
burg Workshop on a Grand Challenge for Proteomics. NIST
was the host, and many federal R&D agencies were repre-
sented. This report summarizes a positive view about the
opportunities to exploit proteomics for the goals of each de-
partment or agency.
Interagency efforts could have four major components: (i)
setting bold programmatic goals for investment in technology
development, (ii) identifying research resources, (iii) pursu-
ing biological applications, and (iv) ensuring coordination
and standardization.
A multiagency effort can highlight opportunities to partici-
pate in pursuing agency-specific priorities with a coordinated
R&D effort to make bold advances in proteomics technolo-
gies. A unified Grand Challenge for Proteomics can increase
prospects for budget synergies for participating agencies and
prospects for a large multiplier in economic activity and job
growth in the relevant applied biotechnology sectors, in part
through private/public partnerships. The National Bioecon-
omy Blueprint released in April 2012 by the White House
Office of Science and Technology Policy highlighted pro-
teomics, together with synthetic biology and bioinformatics,
as “essential foundational technologies” for the bioeconomy
of the future [31]. Finally, such an initiative will enhance
the role of US scientists, institutions, and companies in a
growing, high-profile international S&T endeavor with major
societal benefits for health, agriculture, environment, energy,
and national security.
Contributions of the NIST are not subject to copyright. Copy-
rights to some portions of this white paper (including graphics)
contributed by other workshop participants are reserved by orig-
inal copyright holders or their assignees, and are used here by
permission or under the government’s license.
Certain commercial equipment is identified in this report to
adequately describe experimental procedures. Such identification
does not imply recommendation or endorsement by the NIST, nor
does it imply that the equipment identified is necessarily the best
available for the purpose.
Note that in this document the acronym SRM always refers to
Selective Reaction Monitoring and not NIST Standard Reference
Materials which also use the acronym SRM.
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